Extended lymph node dissection for prostate cancer

Current Urology Reports

Volumn 9, Issue 3, 2008, Pages 237-242

  Jeschke, Stephan ^b   Burkhard, Fiona C ^b   Thurairaja, Ramesh ^b   Dhar, Nivedita ^b   Studer, Urs E ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANATOMY; COMPUTER ASSISTED TOMOGRAPHY; EXTENDED LYMPH NODE DISSECTION; HUMAN; LYMPH NODE DISSECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS LYMPHADENECTOMY; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME;

HUMANS; LYMPH NODE EXCISION; MALE; PROSTATIC NEOPLASMS;

EID: 44449145392     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-008-0041-0     Document Type: Review

References (46)

1. Danella JF, deKernion JB, Smith RB, et al.: The contemporary incidence of lymph node metastases in prostate cancer: implications for laparoscopic lymph node dissection. J Urol 1993, 149:1488-1491.
2. Petros JA, Catalona WJ: Lower incidence of unsuspected lymph node metastasis in 512 consecutive patients with clinically localized prostate cancer. J Urol 1992, 147:1574-1575.
3. Briganti A, Chun FK, Salonia A, et al.: Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU Int 2006, 98:788-793.
4. Bader P, Spahn M, Huber R, et al.: Limited lymph node dissection in prostate cancer may miss lymph node metastases and determines outcome of apparently pN0 prostate cancer [abstract 55]. Eur Urol 2004, 16(Suppl 3).
5. Joslyn SA, Konety BR: Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006, 68:121-125.
6. • Mattei A, Fuechsel FG, Bhatta Dhar N, et al.: The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 2008, 53:118-125. This report shows in a prospective manner the new extent of the primary prostatic lymphatic landing sites.
7. Heidenreich A, von Knobloch R, Varga Z: Extended pelvic lymphadenectomy inpatients undergoing radical prostatectomy in prostate cancer: high incidence of lymph node metastases. J Urol 2001, 167:1681-1684.
8. Heidenreich A, von Knobloch R, Varga Z, Hofmann R: Extended pelvic lymphadenectomy in men undergoing radical retropubic prostatectomy - data on > 300 cases [abstract 4612]. Proc ASCO 2005, 22:409s.
9. Schuhmacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE: Is pelvic lymph node dissection necessary in patients with a serum PSA < 10 ng/ml undergoing radical prostatectomy for prostate cancer? Eur Urol 2006, 50:272-279.
10. Weckermann D, Goppelt M, Dorn R, et al.: Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate specific antigen (PSA) level of < or = 10 ng/ml and biopsy Gleason score of < or = 6, and their influence on PSA progression-free survival after radical prostatectomy. BJU Int 2006, 97:1173-1178.
11. Grossfeld GD, Chang JJ, Broering JM, et al.: Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the cancer of the prostate strategic urologic research endeavor database. J Urol 2001, 165:851-856.
12. Bhatta-Dhar N, Reuther AM, Zippe C, Klein EA: No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer. Urology 2004, 63:528-531.
13. Wolf JS Jr, Cher M, Dall'era M, et al.: The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol 1995, 153:993-999.
14. Tempany CM, McNeil BJ: Advances in biomedical imaging. JAMA 2001, 285:562-567.
15. Borley N, Fabrin K, Sriprasad S, et al.: Laparoscopic pelvic lymph node dissection allows significantly more accurate staging in "high-risk" prostate cancer compared to MRI or CT. Scand J Urol Nephrol 2003, 37:382-386.
16. Harisinghani MG, Barentsz J, Hahn PF, et al.: Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003, 348:2491-2499.
17. Troyer JK, Beckett ML, Wright GL Jr: Location of prostate-specific membrane antigen in the LN CaP prostate carcinoma cell line. Prostate 1997, 30:232-242.
18. Ponsky LE, Cherullo EE, Starkey R, et al.: Evaluation of preoperative ProstaScint scans in the prediction of nodal disease. Prostate Cancer Prostatic Dis 2002, 5:132-135.
19. Katz AE, Olsson CA, Raffo AJ, et al.: Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 1994, 43:765-775.
20. Cabanas RM: An approach for the treatment of penile carcinoma. Cancer 1977, 39:456.
21. Wawroschek F, Vogt H, Weckermann D, Wagner T, et al.: Radioisotope guided pelvic lymph node dissection for prostate cancer. J Urol 2001, 166:1715.
22. Bader P, Burkhard FC, Markwalder R, Studer UE: Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002, 168:514-518.
23. Heidenreich A, Varga Z, Olbert P, Hofmann R: Radical pelvic lymphadenectomy in clinically localised prostate cancer: high frequency of atypical metastasis. Eur Urol 2001, 39(Suppl 5):135.
24. Mattei A, Fuechsel F, Warncke S, et al.: Anatomic localization of prostatic sentinel lymph nodes (SLN) according to fusion imaging of SPECT and CT scans after intraprostatic injection of Technetium-99m-Nanocolloid [abstract 1388]. AUA 2006, 2499.
25. Gronau E, Weckermann D, Harzmann R: Sentinel lymph node resection in prostate cancer patients with a PSA higher than 20ng/ml. J Urol 2005, 173:437.
26. Gil-Vernet JM: Prostate cancer: anatomical and surgical considerations. Brit J Urol 1996, 78:161-168.
27. Raghavaiah NV, Jordan WP: Prostatic lymphography. J Urol 1979, 121:178-181.
28. Wawroschek F, Wagner T, Hamm M, et al.: The influence of serial sections, immunohistochemistry, and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer. Eur Urol 2003, 43:132-137.
29. Stone NN, Stock RG, Unger P: Laparoscopic pelvic lymph node dissection for prostate cancer: comparison to the extended and modified techniques. J Urol 1997, 158:1891-1894.
30. Clark T, Parekh DJ Cookson MS, et al.: Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 2003, 69:145-148.
31. Briganti A, Chun FK-H, Salonia A et al.: Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol 2006, 50:1006-1013.
32. Burkhard FC, Kessler TM, Fleischmann A, et al.: Nerve sparing open radical retropubic prostatectomy: does it have an impact on urinary continence? J Urol 2006, 176:189-195.
33. Michl UH, Friedrich MG, Graefen M, et al.: Prediction of postoperative sexual function after nerve sparing radical retropubic prostatectomy. J Urol 2006, 176:227-231.
34. El-Bahnasawy MS, El-Assmy A, Dawood A, et al.: Effect of the use of internal iliac artery for renal transplantation on penile vascularity and erectile function: a prospective study. J Urol 2004, 172:2335-2339.
35. Aus G, Abbou CC, Bolla M, et al.: EAU guidelines on prostate cancer. Eur Urol 2005, 48:546-551.
36. Golimbu M, Provet J, Al-Askari S, Morales P: Radical prostatectomy for stage D1 prostate cancer. Prognostic variables and results of treatment. Urology 1987, 30:427-435.
37. Catalona WJ, Miller DR, Kavoussi LR: Intermediate-term survival results in clinically understaged prostate cancer patients following radical prostatectomy. J Urol 1988, 140:540-543.
38. Pound CR, Partin AW, Eisenberger MA, et al.: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281:1591-1597.
39. Bader P, Burkhard FC, Markwalder R, Studer UE: Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003, 169:849-854.
40. Daneshmand S, Quek ML, Stein JP, et al.: Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004, 172:2252-2255.
41. Allaf ME, Palapattu GS, Trock BJ, et al.: Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004, 172:1840-1844.
42. • Masterson TA, Bianco FJ Jr, Vickers AJ, et al.: The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 2006, 175:1320-1324; discussion 1324-1325. This report shows that, in men without nodal involvement, an increased number of nodes removed correlates significantly with freedom from biochemical recurrence.
43. • Ferrari AC, Stone NN, Kurek R, et al.: Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. J Clin Oncol 2006, 24:3081-3088. This article discusses an assay that reveals and quantifies clinically relevant occult micrometastases in pathologically negative lymph nodes.
44. Serni S, Masieri L, Minervini A, et al.: Cancer progression after anterograde radical prostatectomy for pathologic Gleason score 8 to 10 and influence of concomitant variables. Urology 2006, 67:373-378.
45. Feinstein AR, Sosin DM, Wells CK: The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985, 312:1604-1608.
46. DiMarco DS, Zincke H, Sebo TJ, et al.: The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol 2005, 173:1121-1125.